The Humoral Response of Patients With Cancer to Breakthrough COVID-19 Infection or the Fourth BNT162b2 Vaccine Dose.

Oncologist · 2023 · PMC10078898 · PMID 36856804

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

fairly significantno p-value reported

Patients in the 4th-BNT162b2-dose group also exhibited a fairly significant increase in anti-SARS-CoV-2 IgG titers at blood-test-2, increasing from 8389.00 AU/mL (IQR[5154.85, 27962.80]) to 22 914.00 AU/mL (IQR [16 562.00, 40 000.00] ( P = .033) ( Fig. 1a ) and compared with the control group ( P < .001) ( Fig. 1b ), highlighting the capacity of the 4th-BNT162b2-dose to bo

also in 163 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.